Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00819
|
|||||
| Drug Name |
Apatinib
|
|||||
| Synonyms |
Apatinib; Apatinib Mesylate; YN968D1; YN-968D1; UNII-TK02X14ASJ; YN 968D1; TK02X14ASJ; 3-Pyridinecarboxamide, N-(4-(1-cyanocyclopentyl)phenyl)-2-((4-pyridinylmethyl)amino)-, methanesulfonate (1:1); Rivoceranib mesylate; 3-Pyridinecarboxamide, N-[4-(1-cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]-, methanesulfonate (1:1); Apatinib-YN968D1; Apatinib - YN968D1; Apatinib (YN968D1); MLS006011286; CHEMBL3545414; KS-00000TST; DTXSID80153427; HMS3655H12; BCP15234; AOB87128; BDBM50152828; s2221; AKOS026750547
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Breast cancer [ICD11: 2C60-2C6Z] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C25H27N5O4S
|
|||||
| Canonical SMILES |
CS(=O)(=O)O.C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4
|
|||||
| InChI |
InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)
|
|||||
| InChIKey |
FYJROXRIVQPKRY-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 1218779-75-9
|
|||||
| Pharmaceutical Properties | Molecular Weight | 493.6 | Topological Polar Surface Area | 153 | ||
| Heavy Atom Count | 35 | Rotatable Bond Count | 6 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 8 | |||
| PubChem CID | ||||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| References | ||||||
| 1 | The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106. (familyId=7648) | |||||
| 2 | Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res. 2010 Oct 15;70(20):7981-91. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.